

Day : Wednesday

Date: 3/28/2007

Time: 08:37:33

 **PALM INTRANET**

## Inventor Information for 10/828795

Inventor Name	City	State/Country
WEBER, ECKARD	SAN DIEGO	CALIFORNIA
COWLEY, MICHAEL ALEXANDER	PORTLAND	OREGON

Appln Info	Contents	Petition Info	Atty/Agent Info	Continuity/Reexam	Foreign I
------------	----------	---------------	-----------------	-------------------	-----------

Search Another: Application#   or Patent#  PCT /  /   or PG PUBS #  Attorney Docket #  Bar Code #  

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

(FILE 'HOME' ENTERED AT 09:11:35 ON 28 MAR 2007)

FILE 'REGISTRY' ENTERED AT 09:11:46 ON 28 MAR 2007

L1 191 S NALTREXONE  
L2 0 S NALTREXONE/CT  
L3 1 S NALTREXONE/CN  
L4 1 S BUPROPION/CN

FILE 'CAPLUS' ENTERED AT 09:12:22 ON 28 MAR 2007

FILE 'REGISTRY' ENTERED AT 09:12:31 ON 28 MAR 2007

SET SMARTSELECT ON  
L5 SEL L3 1- CHEM : 12 TERMS  
SET SMARTSELECT OFF

FILE 'CAPLUS' ENTERED AT 09:12:31 ON 28 MAR 2007

L6 4022 S L5  
L7 4022 S L6 OR NALTREXONE?

FILE 'REGISTRY' ENTERED AT 09:12:56 ON 28 MAR 2007

SET SMARTSELECT ON  
L8 SEL L4 1- CHEM : 8 TERMS  
SET SMARTSELECT OFF

FILE 'CAPLUS' ENTERED AT 09:12:57 ON 28 MAR 2007

L9 1392 S L8  
L10 1394 S L9 OR BUPROPION?  
L11 1392 S L9 AND L10  
L12 51 S L10 AND L7  
L13 5 S L12 AND (EXTENDED? OR CONTROLLED OR SLOW RELEASE OR LONG ACTI  
L14 5 FOCUS L13 1-

FILE 'USPATFULL' ENTERED AT 09:16:47 ON 28 MAR 2007

=> s l12

REFERENCED SmartSELECT L-NUMBERS CAN NOT BE SEARCHED  
SmartSELECT L-numbers may be combined with other logic in the same  
search when entered at the level one prompt. Referenced SmartSELECT  
L-numbers can not be searched when combined with additional terms.  
This can occur when searching an L-number answer set in a file other  
than where it was created.

=> s l3 and l4

365 L3  
320 L4  
L15 21 L3 AND L4

=> s l15 and (extended? or controlled or slow release or long acting or  
slow-released or long-acting)

824870 EXTENDED?  
1629411 CONTROLLED  
1 CONTROLLEDSDS  
1629411 CONTROLLED  
(CONTROLLED OR CONTROLLEDSDS)  
421531 SLOW  
42040 SLOWS  
446283 SLOW  
(SLOW OR SLOWS)  
713004 RELEASE  
169635 RELEASES  
774036 RELEASE  
(RELEASE OR RELEASES)  
20352 SLOW RELEASE

(SLOW(W) RELEASE)  
 1782009 LONG  
     522 LONGS  
 1782102 LONG  
     (LONG OR LONGS)  
 507890 ACTING  
     12 ACTINGS  
 507897 ACTING  
     (ACTING OR ACTINGS)  
     9354 LONG ACTING  
         (LONG(W)ACTING)  
 421531 SLOW  
     42040 SLOWS  
 446283 SLOW  
     (SLOW OR SLOWS)  
 594894 RELEASED  
     71 SLOW-RELEASED  
         (SLOW(W) RELEASED)  
 1782009 LONG  
     522 LONGS  
 1782102 LONG  
     (LONG OR LONGS)  
 507890 ACTING  
     12 ACTINGS  
 507897 ACTING  
     (ACTING OR ACTINGS)  
     9354 LONG-ACTING  
         (LONG(W)ACTING)

L16           17 L15 AND (EXTENDED? OR CONTROLLED OR SLOW RELEASE OR LONG ACTING  
                   OR SLOW-RELEASED OR LONG-ACTING)

=> focus

PROCESSING COMPLETED FOR L16

L17           17 FOCUS L16 1-

=> d ibib abs hitstr 1-17

L17 ANSWER 1 OF 17 USPATFULL on STN

ACCESSION NUMBER:       2003:207910 USPATFULL

TITLE:               Methods for the treatment of substance abuse

INVENTOR(S):          Shulman, Albert, Victoria, AUSTRALIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003144271	A1	20030731
APPLICATION INFO.:	US 2002-181990	A1	20021106 (10)
	WO 2001-AU60		20010122

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-1390	20000122
	GB 2000-1647	20000126
	AU 2000-2237	20001221
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1593	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB    The present invention relates to methods of therapy for substance  
 addiction comprising the administration to a subject in need thereof a  
 combination of: (i) a  $\mu$ -opioid receptor antagonist; (ii) a calcium

channel blocker which is **long-acting** or in sustained-release form or which is nimodipine in rapid release form; and (iii) an NMDA glutamate receptor modulator; as well as combinations, kits and composition useful therefor.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **16590-41-3**, Naltrexone **34911-55-2**, Bupropion ( $\mu$  opioid antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance abuse)

RN 16590-41-3 USPATFULL


CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 2 OF 17 USPATFULL on STN

ACCESSION NUMBER: 96:7552 USPATFULL

TITLE: **Controlled**, sustained release delivery system for treating drug dependency

INVENTOR(S): Kitchell, Judith P., Newton, MA, United States  
Muni, Indu A., N. Reading, MA, United States  
Boyer, Yvonne N., Salem, MA, United States

PATENT ASSIGNEE(S): DynaGen, Inc., Cambridge, MA, United States (U.S. corporation)


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5486362		19960123
APPLICATION INFO.:	US 1993-140280		19931021 (8)
DISCLAIMER DATE:	20120404		
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-880959, filed on 7 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-696637, filed on 7 May 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

PRIMARY EXAMINER: Page, Thurman K.  
ASSISTANT EXAMINER: Azpuru, Carlos A.  
LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks  
NUMBER OF CLAIMS: 15  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 9 Drawing Page(s)  
LINE COUNT: 1132  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A drug delivery system useful in treating an individual for a drug dependence is described. One embodiment of the system is useful for aiding individuals in the cessation of smoking or chewing nicotine containing products is described. The delivery system includes a physical constraint modulation system (PCMS.TM.) containing lobeline. The drug delivery system is capable of delivering lobeline to an individual in a **controlled**, sustained release manner and providing long-term therapeutic levels of lobeline to the individual. The delivery of lobeline in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the lobeline capable of subcutaneous or intramuscular injection or implantation into the individual or may be part of a transdermal patch containing lobeline. Also described are methods of using the drug delivery systems in treating other drug dependencies and kits containing the drug delivery systems.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 34911-55-2, Amfebutamone  
(drug delivery system containing, for cocaine dependence treatment)  
RN 34911-55-2 USPATFULL  
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



IT 16590-41-3, Naltrexone  
(drug delivery system containing, for heroin dependence treatment)  
RN 16590-41-3 USPATFULL  
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER: 96:62895 USPATFULL  
 TITLE: **Controlled**, sustained release delivery system  
 for smoking cessation  
 INVENTOR(S): Kitchell, Judith P., Newton, MA, United States  
 Muni, Indu A., N. Reading, MA, United States  
 Boyer, Yvonne N., Salem, MA, United States  
 PATENT ASSIGNEE(S): DynaGen, Inc., Cambridge, MA, United States (U.S.  
 corporation)


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5536503		19960716
APPLICATION INFO.:	US 1995-415859		19950403 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-135847, filed on 13 Oct 1993, now patented, Pat. No. US 5403595 which is a continuation of Ser. No. US 1992-881740, filed on 7 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-696637, filed on 7 May 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Azpuru, Carlos		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	946		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A drug delivery system useful in aiding individuals in the cessation of smoking or chewing nicotine containing products is described. The delivery system includes a physical constraint modulation system (PCMS.TM.) containing lobeline. The drug delivery system is capable of delivering lobeline to an individual in a **controlled**, sustained release manner and providing long-term therapeutic levels of lobeline to the individual. The delivery of lobeline in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the lobeline capable of subcutaneous or intramuscular injection or implantation into the individual or may be part of a transdermal patch containing lobeline. Also described are methods of using the drug delivery systems and kits containing the drug delivery systems.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **34911-55-2**, Amfebutamone  
 (drug delivery system containing, for cocaine dependence treatment)  
 RN 34911-55-2 USPATFULL  
 CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



IT **16590-41-3**, Naltrexone  
 (drug delivery system containing, for heroin dependence treatment)  
 RN 16590-41-3 USPATFULL  
 CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 4 OF 17 USPATFULL on STN

ACCESSION NUMBER: 95:29402 USPATFULL

TITLE: **Controlled**, sustained release delivery system for smoking cessation

INVENTOR(S): Kitchell, Judith P., Newton, MA, United States  
Muni, Indu A., N. Reading, MA, United States  
Boyer, Yvonne N., Salem, MA, United States

PATENT ASSIGNEE(S): DynaGen, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5403595		19950404
APPLICATION INFO.:	US 1993-135847		19931013 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-881740, filed on 7 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-696637, filed on 7 May 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Azpuru, Carlos		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	946		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A drug delivery system useful in aiding individuals in the cessation of smoking or chewing nicotine containing products is described. The delivery system includes a physical constraint modulation system (PCMS.TM.) containing lobeline. The drug delivery system is capable of delivering lobeline to an individual in a **controlled**, sustained release manner and providing long-term therapeutic levels of lobeline to the individual. The delivery of lobeline in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the lobeline capable of subcutaneous or intramuscular injection or implantation into the individual or may be part of a transdermal patch containing lobeline. Also described are methods of using the drug delivery systems and kits containing the drug delivery systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT **34911-55-2**, Amfebutamone

(drug delivery system containing, for cocaine dependence treatment)

RN 34911-55-2 USPATFULL

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX

NAME)




IT 16590-41-3, Naltrexone

(drug delivery system containing, for heroin dependence treatment)

RN 16590-41-3 USPATFULL

CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-,  
(5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 5 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2004:69635 USPATFULL

TITLE: Use of GLP for the treatment, prevention, diagnosis,  
and prognosis of bone-related and nutrition-related  
disorders

INVENTOR(S): Henriksen, Dennis B., Alleroed, DENMARK  
Holst, Jens J., Hellerup, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004052862	A1	20040318
	US 7186683	B2	20070306
APPLICATION INFO.:	US 2003-393524	A1	20030320 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-954304, filed on 17 Sep 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-22844	20000918
	GB 2000-29920	20001207
	US 2002-371307P	20020410 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EDWARDS & ANGELL, LLP, P.O. BOX 9169, BOSTON, MA, 02209	
NUMBER OF CLAIMS:	68	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	3496	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for prevention and treatment of




bone-related or nutrition-related disorders using a GLP molecule or GLP activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 16590-41-3, Naltrexone 34911-55-2, Bupropion  
(in GLP formulations; pharmaceutical compns. and methods for use of glucagon-like peptides (GLP) analogs in treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders)  
RN 16590-41-3 USPATFULL  
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL  
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 6 OF 17 USPATFULL on STN  
ACCESSION NUMBER: 2006:167779 USPATFULL  
TITLE: Compositions for affecting weight loss  
INVENTOR(S): Weber, Eckard, San Diego, CA, UNITED STATES  
Cowley, Michael Alexander, Portland, OR, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006142290	A1	20060629
APPLICATION INFO.:	US 2006-356839	A1	20060217 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-828795, filed on 21 Apr 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-466838P	20030429 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

11/356839

LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET,  
FOURTEENTH FLOOR, IRVINE, CA, 92614, US

NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM: 1

LINE COUNT: 1656

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance  $\alpha$ -MSH activity.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 16590-41-3, Naltrexone 34911-55-2, Bupropion  
(compsn. containing opioid antagonist and melanocortin agonist for affecting weight loss)

RN 16590-41-3 USPATFULL


CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-,  
(5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 7 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2004:321553 USPATFULL

TITLE: Compositions for affecting weight loss

INVENTOR(S): Weber, Eckard, San Diego, CA, UNITED STATES

Cowley, Michael Alexander, Portland, OR, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004254208	A1	20041216

APPLICATION INFO.: US 2004-828795 A1 20040421 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-466838P	20030429 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1718	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance  $\alpha$ -MSH activity.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 16590-41-3, Naltrexone 34911-55-2, Bupropion  
(comps. containing opioid antagonist and melanocortin agonist for affecting weight loss)

RN 16590-41-3 USPATFULL


CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-,  
(5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 8 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2005:221541 USPATFULL

TITLE: Azabicyclic heterocycles as cannabinoid receptor modulators  
INVENTOR(S): Ewing, William R., Yardley, PA, UNITED STATES  
Yu, Guixue, Princeton Junction, NJ, UNITED STATES  
Ellsworth, Bruce A., Princeton, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005192278	A1	20050901
	US 7037910	B2	20060502
APPLICATION INFO.:	US 2004-15876	A1	20041217 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-531451P	20031219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1646	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I ##STR1## including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are described herein.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 16590-41-3, Naltrexone 34911-55-2, Bupropion  
(co-drug; preparation of azabicyclic heterocycles as cannabinoid receptor modulators)  
RN 16590-41-3 USPATFULL  
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-,  
(5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL  
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 9 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2005:196967 USPATFULL

TITLE: Azabicyclic heterocycles as cannabinoid receptor modulators

INVENTOR(S): Yu, Guixue, Princeton Junction, NJ, UNITED STATES  
 Ewing, William R., Yardley, PA, UNITED STATES  
 Mikkilineni, Amarendra B., Easton, PA, UNITED STATES  
 Pendri, Annapurna, Glastonbury, CT, UNITED STATES  
 Ellsworth, Bruce A., Princeton, NJ, UNITED STATES  
 Sher, Philip M., Plainsboro, NJ, UNITED STATES  
 Gerritz, Samuel, Guilford, CT, UNITED STATES  
 Sun, Chongqing, East Windsor, NJ, UNITED STATES  
 Murugesan, Natesan, Princeton Junction, NJ, UNITED STATES  
 Wu, Ximao, Princeton Junction, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005171110	A1	20050804
APPLICATION INFO.:	US 2004-16198	A1	20041217 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-531451P	20031219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US	
NUMBER OF CLAIMS:	73	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2556	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I. ##STR1## including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, m and n are described herein.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 16590-41-3, Naltrexone 34911-55-2, Bupropion  
 (co-drug; preparation of azabicyclic heterocycles as cannabinoid receptor modulators)  
 RN 16590-41-3 USPATFULL  
 CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL  
 CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 10 OF 17 USPATFULL on STN  
 ACCESSION NUMBER: 2005:165956 USPATFULL  
 TITLE: Azabicyclic heterocycles as cannabinoid receptor modulators  
 INVENTOR(S): Yu, Guixue, Princeton Junction, NJ, UNITED STATES  
 Ewing, William R., Yardley, PA, UNITED STATES  
 Mikkilineni, Amarendra B., Easton, PA, UNITED STATES  
 Pendri, Annapurna, Glastonbury, CT, UNITED STATES  
 Sher, Philip M., Plainsboro, NJ, UNITED STATES  
 Gerritz, Samuel, Guilford, CT, UNITED STATES  
 Ellsworth, Bruce A., Princeton, NJ, UNITED STATES  
 Wu, Gang, Princeton, NJ, UNITED STATES  
 Huang, Yanting, Pennington, NJ, UNITED STATES  
 Sun, Chongqing, East Windsor, NJ, UNITED STATES  
 Murugesan, Natesan, Princeton Junction, NJ, UNITED STATES  
 Gu, Zhengxiang, Princeton, NJ, UNITED STATES  
 Wang, Ying, Princeton, NJ, UNITED STATES  
 Sitkoff, Doree, Dresher, PA, UNITED STATES  
 Johnson, Stephen R., Erdenheim, PA, UNITED STATES  
 Wu, Ximao, Princeton Junction, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005143381	A1	20050630
APPLICATION INFO.:	US 2004-16135	A1	20041217 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-531451P	20031219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US	
NUMBER OF CLAIMS:	73	
EXEMPLARY CLAIM:	1	


LINE COUNT: 5350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: ##STR1## including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, m and n are described herein.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 16590-41-3, Naltrexone 34911-55-2, Bupropion  
(co-drug; preparation of azabicyclic heterocycles as cannabinoid receptor modulators)  
RN 16590-41-3 USPATFULL  
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-,  
(5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL  
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 11 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2004:308298 USPATFULL

TITLE: Treatment of refractory depression with an opiate antagonist and an antidepressant

INVENTOR(S): Glover, Hillel, New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004242974	A1	20041202
APPLICATION INFO.:	US 2004-878285	A1	20040629 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-925190, filed on 9 Aug 2001, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP, 2101 L STREET		

NW, WASHINGTON, DC, 20037-1526

NUMBER OF CLAIMS: 57

EXEMPLARY CLAIM: 1

LINE COUNT: 1056

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An antidepressant or a pharmaceutically acceptable salt thereof, and an opiate antagonist or a pharmaceutically acceptable salt thereof, are used to treat refractory depression characterized by dissociation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 16590-41-3, Naltrexone

(opiate antagonist and antidepressant for treatment of refractory depression with dissociation)

RN 16590-41-3 USPATFULL

CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.




IT 34911-55-2, Bupropion SR

(opiate antagonist and antidepressant for treatment of refractory depression with dissociation)

RN 34911-55-2 USPATFULL

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 12 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2004:261970 USPATFULL

TITLE: Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents

INVENTOR(S): Briggs, Michael, Shrewsbury, MA, UNITED STATES  
Hauser, Scott, St. Louis, MO, UNITED STATES  
Ornberg, Richard, Hayward, CA, UNITED STATES  
Koki, Alane, Marseille, FRANCE

PATENT ASSIGNEE(S): Pharmacia Corporation, Chesterfield, MO (U.S. corporation)

NUMBER KIND DATE

-----



PATENT INFORMATION: US 2004204472 A1 20041014  
 APPLICATION INFO.: US 2004-773019 A1 20040205 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-451885P	20030304 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Charles E. Dunlap, P.O. Box 11070, Columbia, SC, 29211-1070	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5174	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for preventing or treating obesity and obesity-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a conventional weight-loss agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a conventional weight-loss agent. Pharmaceutical compositions and kits for implementing the present method are also described.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 16590-41-3, Naltrexone 34911-55-2, Bupropion  
 (treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents)

RN 16590-41-3 USPATFULL


CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 13 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2003:127681 USPATFULL

TITLE: Treatment of refractory depression with an opiate antagonist and an antidepressant

INVENTOR(S): Glover, Hillel, New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087896	A1	20030508
APPLICATION INFO.:	US 2001-925190	A1	20010809 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP, 2101 L STREET NW, WASHINGTON, DC, 20037-1526		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
LINE COUNT:	714		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB An antidepressant or a pharmaceutically acceptable salt thereof, and an opiate antagonist or a pharmaceutically acceptable salt thereof, are used to treat refractory depression characterized by dissociation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 34911-55-2, Bupropion SR  
(as antidepressant; refractory depression treatment with opiate antagonist and antidepressant)

RN 34911-55-2 USPATFULL

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)




IT 16590-41-3, Naltrexone  
(as opiate antagonist; refractory depression treatment with opiate antagonist and antidepressant)

RN 16590-41-3 USPATFULL

CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 14 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2001:173165 USPATFULL

TITLE: Methods and pharmaceutical compositions employing desmethylselegiline

INVENTOR(S): DiSanto, Anthony R., Gobles, MI, United States

PATENT ASSIGNEE(S): Blume, Cheryl D., Tampa, FL, United States(4)  
Somerset Pharmaceuticals, Inc., Tampa, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6299901	B1	20011009
APPLICATION INFO.:	US 1999-262845		19990305 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-679330, filed on 12 Jul 1996 Continuation-in-part of Ser. No. WO 1996-US1561, filed on 11 Jan 1996 Continuation-in-part of Ser. No. US 1995-372139, filed on 13 Jan 1995		


	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-1979P	19950731 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Jones, Dameron L.	
LEGAL REPRESENTATIVE:	Vinson & Elkins LLP	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Figure(s); 17 Drawing Page(s)	
LINE COUNT:	1573	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The application is directed to the treatment of one or more symptoms associated with drug withdrawal by administering desmethylselegiline.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 34911-55-2, Bupropion  
(desmethylselegiline for treating drug withdrawal-associated symptoms)  
RN 34911-55-2 USPATFULL  
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



IT 16590-41-3, Naltrexone  
(desmethylselegiline for treating drug withdrawal-associated symptoms)  
RN 16590-41-3 USPATFULL  
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 15 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2005:287501 USPATFULL

TITLE: Use of N-desmethyloclozapine to treat human neuropsychiatric disease

INVENTOR(S): Weiner, David M., San Diego, CA, UNITED STATES  
Brann, Mark R., Del Mar, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005250767	A1	20051110
APPLICATION INFO.:	US 2005-98892	A1	20050404 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-913117, filed on 5 Aug 2004, PENDING Continuation-in-part of Ser. No. US 2004-761787, filed on 21 Jan 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-442690P	20030123 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	2415	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethyloclozapine to a patient suffering from a neuropsychiatric disease.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 16590-41-3, Naltrexone 34911-55-2, Bupropion  
(use of desmethyloclozapine to treat human neuropsychiatric disease)

RN 16590-41-3 USPATFULL


CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-,  
(5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 16 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2005:99544 USPATFULL

TITLE: Use of N-desmethyldespropylclozapine to treat human neuropsychiatric disease

INVENTOR(S): Weiner, David M., San Diego, CA, UNITED STATES  
Brann, Mark R., Del Mar, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005085463	A1	20050421
APPLICATION INFO.:	US 2004-913117	A1	20040805 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-761787, filed on 21 Jan 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-442690P	20030123 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	2145	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethyldespropylclozapine to a patient suffering from a neuropsychiatric disease.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 16590-41-3, Naltrexone 34911-55-2, Bupropion  
(use of N-desmethyldespropylclozapine to treat human neuropsychiatric disease)


RN 16590-41-3 USPATFULL

CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-,  
(5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL  
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 17 OF 17 USPATFULL on STN  
ACCESSION NUMBER: 2001:160986 USPATFULL  
TITLE: Use of sulfamate derivatives for treating impulse control disorders  
INVENTOR(S): McElroy, Susan L., Cincinnati, OH, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001023254	A1	20010920
	US 6323236	B2	20011127
APPLICATION INFO.:	US 2000-506991	A1	20000218 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FROST BROWN TODD, LLC, 2200 PNC CENTER, 201 E. FIFTH STREET, CINCINNATI, OH, 45202		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	933		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Impulse Control Disorders (ICD's) are characterized by harmful behaviors performed in response to irresistible impulses. The essential feature of an ICD is the failure to resist an impulse, drive, or temptation and to perform an act that is harmful to the person or to others. The present invention comprises methods for the treatment or prevention of ICD's using a class of sulfamates of the following formula: ##STR1##

wherein X is CH<sub>2</sub> or oxygen, and R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are as herein defined. Further, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and intermediates form part of the present invention are also disclosed.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 16590-41-3, Naltrexone 34911-55-2, Bupropion (sulfamate derivs. for treatment of impulse control disorders, and use with other agents)

RN 16590-41-3 USPATFULL


CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX  
NAME)



result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:11:35 ON 28 MAR 2007

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:11:46 ON 28 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 MAR 2007 HIGHEST RN 928296-91-7  
DICTIONARY FILE UPDATES: 27 MAR 2007 HIGHEST RN 928296-91-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s naltrexone  
L1 191 NALTREXONE  
  
=> s naltrexone/ct  
'CT' IS NOT A VALID FIELD CODE  
L2 0 NALTREXONE/CT  
  
=> s naltrexone/cn  
L3 1 NALTREXONE/CN  
  
=> s bupropion/cn  
L4 1 BUPROPION/CN

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	15.30	15.51

FILE 'CAPLUS' ENTERED AT 09:12:22 ON 28 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.



The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Mar 2007 VOL 146 ISS 14  
FILE LAST UPDATED: 27 Mar 2007 (20070327/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 <> or naltrexone?

**SmartSELECT INITIATED**

New TRANSFER and ANALYZE Commands Now Available  
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.47	15.98

FILE 'REGISTRY' ENTERED AT 09:12:31 ON 28 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

SET SMARTSELECT ON  
SET COMMAND COMPLETED

SEL L3 1-  
L5 SEL L3 1- CHEM : 12 TERMS

SET SMARTSELECT OFF  
SET COMMAND COMPLETED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.65	27.63

FILE 'CAPLUS' ENTERED AT 09:12:31 ON 28 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

S L5 OR NALTREXONE?

L7 3904 NALTREXONE?  
4022 L6 OR NALTREXONE?

=> s l4 <> or bupropion?

**SmartSELECT INITIATED**

New TRANSFER and ANALYZE Commands Now Available  
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
----------------------	------------------	---------------

FULL ESTIMATED COST 46.70 74.33

FILE 'REGISTRY' ENTERED AT 09:12:56 ON 28 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

SET SMARTSELECT ON  
SET COMMAND COMPLETED

SEL L4 1-  
L8 SEL L4 1- CHEM : 8 TERMS

SET SMARTSELECT OFF  
SET COMMAND COMPLETED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.65	85.98

FILE 'CAPLUS' ENTERED AT 09:12:57 ON 28 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

S L8 OR BUPROPION?

L10 1353 BUPROPION?  
1394 L9 OR BUPROPION?

=> s l9 and l10  
L11 1392 L9 AND L10

=> d his

(FILE 'HOME' ENTERED AT 09:11:35 ON 28 MAR 2007)

FILE 'REGISTRY' ENTERED AT 09:11:46 ON 28 MAR 2007  
L1 191 S NALTREXONE  
L2 0 S NALTREXONE/CT  
L3 1 S NALTREXONE/CN  
L4 1 S BUPROPION/CN

FILE 'CAPLUS' ENTERED AT 09:12:22 ON 28 MAR 2007

FILE 'REGISTRY' ENTERED AT 09:12:31 ON 28 MAR 2007  
SET SMARTSELECT ON  
L5 SEL L3 1- CHEM : 12 TERMS  
SET SMARTSELECT OFF

FILE 'CAPLUS' ENTERED AT 09:12:31 ON 28 MAR 2007  
L6 4022 S L5  
L7 4022 S L6 OR NALTREXONE?

FILE 'REGISTRY' ENTERED AT 09:12:56 ON 28 MAR 2007  
SET SMARTSELECT ON  
L8 SEL L4 1- CHEM : 8 TERMS  
SET SMARTSELECT OFF

FILE 'CAPLUS' ENTERED AT 09:12:57 ON 28 MAR 2007  
L9 1392 S L8  
L10 1394 S L9 OR BUPROPION?

L11 1392 S L9 AND L10

=> s l10 and l7

L12 51 L10 AND L7

=> s l12 and (extended? or controlled or slow release or long acting or slow-released or long-acting)

253679 EXTENDED?

554221 CONTROLLED

1 CONTROLLED

554221 CONTROLLED

(CONTROLLED OR CONTROLLED)

228598 SLOW

7403 SLOWS

235338 SLOW

(SLOW OR SLOWS)

488279 RELEASE

24436 RELEASES

502938 RELEASE

(RELEASE OR RELEASES)

8512 SLOW RELEASE

(SLOW(W) RELEASE)

781774 LONG

23 LONGS

781795 LONG

(LONG OR LONGS)

113830 ACTING

5 ACTINGS

113835 ACTING

(ACTING OR ACTINGS)

7480 LONG ACTING

(LONG(W) ACTING)

228598 SLOW

7403 SLOWS

235338 SLOW

(SLOW OR SLOWS)

178343 RELEASED

106 SLOW-RELEASED

(SLOW(W) RELEASED)

781774 LONG

23 LONGS

781795 LONG

(LONG OR LONGS)

113830 ACTING

5 ACTINGS

113835 ACTING

(ACTING OR ACTINGS)

7480 LONG-ACTING

(LONG(W) ACTING)

L13 5 L12 AND (EXTENDED? OR CONTROLLED OR SLOW RELEASE OR LONG ACTING OR SLOW-RELEASED OR LONG-ACTING)

=> focus

PROCESSING COMPLETED FOR L13

L14 5 FOCUS L13 1-

=> d ibib abs hitstr 1-5

L14 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:45784 CAPLUS

DOCUMENT NUMBER: 118:45784

TITLE: A **controlled**, sustained-release delivery system for treating drug dependency

INVENTOR(S): Kitchell, Judith P.; Muni, Indu A.; Boyer, Yvonne N.

PATENT ASSIGNEE(S): Dynagen, Inc., USA  
 SOURCE: PCT Int. Appl., 67 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9219226	A1	19921112	WO 1992-US3859	19920507
W: AU, CA, FI, HU, JP, KR, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2102507	A1	19921108	CA 1992-2102507	19920507
AU 9221548	A	19921221	AU 1992-21548	19920507
HU 69390	A2	19950928	HU 1993-3146	19920507
US 5486362	A	19960123	US 1993-140280	19931021
PRIORITY APPLN. INFO.:			US 1991-696637	A 19910507
			US 1992-880959	B1 19920507
			WO 1992-US3859	A 19920507

AB A drug delivery system useful in treating an individual for drug dependence is described. One embodiment of the system is useful for aiding individuals in the cessation of smoking or chewing nicotine-containing products. The delivery system includes a phys. constraint modulation system (PCMS) containing lobeline (I). The drug delivery system is capable of delivering I to an individual in a **controlled**, sustained-release manner and providing long-term therapeutic levels of I to the individual. The delivery of I in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the I capable of s.c. or i.m. injection or implantation into the individual or may be a part of a transdermal patch containing I. Also described are methods of using the drug delivery systems in treating other drug dependencies and kits containing the drug delivery systems. A suspension formulation for s.c. administration was prepared which included lactic acid-glycolic acid copolymer microparticles containing 35 weight% I. In tests with volunteers, the formulation substantially decreased the number of cigarettes smoked.


IT **34911-55-2, Amfebutamone**

RL: BIOL (Biological study)

(drug delivery system containing, for cocaine dependence treatment)

RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



IT **16590-41-3, Naltrexone**


RL: BIOL (Biological study)

(drug delivery system containing, for heroin dependence treatment)

RN 16590-41-3 CAPLUS

CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:197273 CAPLUS

DOCUMENT NUMBER: 136:379380

TITLE: Drug addiction. Part III. Pharmacotherapy of addiction

AUTHOR(S): Vetulani, Jerzy

CORPORATE SOURCE: Institute of Pharmacology, Polish Academy of Sciences, Krakow, PL-31-343, Pol.

SOURCE: Polish Journal of Pharmacology (2001), 53(5), 415-434  
CODEN: PJPAE3; ISSN: 1230-6002

PUBLISHER: Polish Academy of Sciences, Institute of Pharmacology

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. The last decade brought a considerable progress in pharmacotherapy of addiction. Basing on recently gained knowledge of mechanisms of development of addiction and the physiol. of the brain reward system, several therapeutic strategies have evolved. The strategies aimed at targeting the basic mechanisms of addiction rely on the premises that addiction is caused by adaptive changes in the central nervous system and that craving, which is the main cause of relapse, depends on dopaminergic mechanisms and requires high general excitability. The pharmacol. approach involves drugs that reduce neuronal adaptability by inhibiting the calcium entry to neurons both through voltage-gated channels (e.g. nimodipine) and NMDA receptors (e.g. memantine), and drugs that stimulate the inhibitory GABAergic system ( $\gamma$ -vinyl-GABA, baclofen). Particular attention is paid to the compds. that may attenuate dopaminergic hyperactivity, without considerable suppression of tonic activity of dopaminergic neurons (e.g. BP 897, a partial dopamine D3 receptor antagonist). Specific strategies are aimed at interference with the action of particular drugs of addiction. An important group includes the agonistic therapies (known also as substitution or maintenance therapies) in which a **long-acting** agonist is used in order to reduce the action of the drugs of high addictive potential (e.g. methadone against heroin addiction or vanoxerine (GBR 12909) against psychostimulants). Other specific strategies aimed at reduction of the transport of mols. of addictive substances into the brain: the approaches involve preparation of antibodies that form complexes unable to cross blood-brain barrier or enzymes accelerating the metabolism of the compds. in the blood (e.g. variants of butyrylcholinesterase). A considerable progress has been made in combating the abuse of legal addictive substances, alc. (**naltrexone**, acamprosate) and tobacco (**bupropion**). The prospects for developing effective pharmacotherapies against addiction are bright. Unfortunately, ideol. and social implications, as well as the conflict of interest with illegal narcotic manufacturers and distributors, may considerably hamper the progress in combating addiction (e.g. difficulties in introduction of methadone).

IT 16590-41-3, Naltrexone 34911-55-2,  
**Bupropion**


RL: DMA (Drug mechanism of action); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmacotherapy of drug addiction)

RN 16590-41-3 CAPLUS


CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-,  
(5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 155 THERE ARE 155 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:545488 CAPLUS

DOCUMENT NUMBER: 135:117246

TITLE: Methods using a  $\mu$  opioid antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for the treatment of substance abuse

INVENTOR(S): Shulman, Albert

PATENT ASSIGNEE(S): Australia

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001052851	A1	20010726	WO 2001-AU60	20010122
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,			

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2397726	A1	20010726	CA 2001-2397726	20010122
AU 2001026574	A5	20010731	AU 2001-26574	20010122
EP 1250136	A1	20021023	EP 2001-901062	20010122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003520234	T	20030702	JP 2001-552898	20010122
NO 2002003482	A	20020919	NO 2002-3482	20020722
ZA 2002005839	A	20030722	ZA 2002-5839	20020722
US 2003144271	A1	20030731	US 2002-181990	20021106
PRIORITY APPLN. INFO.:			GB 2000-1390	A 20000122
			GB 2000-1647	A 20000126
			AU 2000-2237	A 20001221
			AU 2000-22370	A 20001221
			WO 2001-AU60	W 20010122

AB Methods are provided for therapy for substance (e.g. alc.) addiction which comprise the administration of a combination of (i) a  $\mu$ -opioid receptor antagonist; (ii) a calcium channel blocker which is **long-acting** or in sustained-release form or which is nimodipine in rapid release form; and (iii) an NMDA glutamate receptor modulator. Also provided are combinations, kits and compns. useful therefor.

IT **16590-41-3, Naltrexone 34911-55-2, Bupropion**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

( $\mu$  opioid antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance abuse)

RN 16590-41-3 CAPLUS


CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2007:83392 CAPLUS

DOCUMENT NUMBER: 146:163111

TITLE: Pyrazolines as antiaddictive agents ad their preparation, and pharmaceutical active substance combination

INVENTOR(S): Buschmann, Helmut H.

PATENT ASSIGNEE(S): Laboratorios del Dr. Esteve, S. A., Spain

SOURCE: PCT Int. Appl., 76pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007009691	A2	20070125	WO 2006-EP6965	20060715
WO 2007009691	A3	20070308		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1749525	A1	20070207	EP 2005-384009	20050715
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
PRIORITY APPLN. INFO.:			EP 2005-384009	A 20050715
			US 2005-705483P	P 20050805

OTHER SOURCE(S): MARPAT 146:163111

GI



AB The invention relates to an active substance combination comprising at least one substituted pyrazoline compound of formula I, and at least one



anti-addictive compound, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament. Compds. of formula I wherein R1 and R2 are independently (un)substituted Ph; R3 is (un)substituted (un)saturated (hetero)cyclcyl, (un)substituted phenyl; and their stereoisomers, enantiomers, diastereoisomer, racemates, mixture of stereoisomer, mixture of diastereoisomers, mixture of enantiomers, pharmaceutically acceptable salts, solvates and N-oxides, thereof, are claimed. Example compound II was prepared by condensation of 4-chlorobenzaldehyde with Et pyruvate; the resulting trans-4-(4-chlorophenyl)-2-oxo-3-butenic acid underwent cyclization with 2,4-dichlorophenylhydrazine hydrochloride to give 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydropyrazole-3-carboxylic acid, which underwent chlorination to give the corresponding acid chloride, which underwent amidation with 1-aminopiperidine to give compound II. All the invention compds. were evaluated for their CB1 and CB2 receptor affinity. From the assay, it was determined that compound II exhibited 93 % inhibition at 10<sup>-6</sup> M concentration and a Ki value of < 25 nM against CB1, and 33 % inhibition (10<sup>-6</sup> M) and > 1000 nM against CB2.

IT 16590-41-3, Naltrexone 34911-55-2,

**Bupropion**


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(codrug; preparation of pyrazolines as antiaddictive agents and their active substance combination)

RN 16590-41-3 CAPLUS


CN. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L14 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1124114 CAPLUS

DOCUMENT NUMBER: 145:455030

TITLE: Preparation of substituted heteroaryl CB1 antagonists



INVENTOR(S): Yuan, Jun; Guo, Qin; Zhao, He; Hu, Shaojing;

Whitehouse, Darren; Fringle, Wallace; Mao, Jianmin;  
 Maynard, George; Hammer, Jack; Wustrow, David; Li,  
 Hongbin  
 PATENT ASSIGNEE(S): Neurogen Corporation, USA  
 SOURCE: PCT Int. Appl., 447pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006113704	A2	20061026	WO 2006-US14548	20060418
WO 2006113704	A3	20070208		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,  
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
 VN, YU, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-672452P P 20050418  
 OTHER SOURCE(S): MARPAT 145:455030  
 GI



AB The title compds. I [A = CR1 or N; Ar1, Ar2 = (un)substituted 5-10 membered carbocycle and heterocycle; X = (un)substituted CH2, O, NH or SOmNH; m = 0-2; Y = (un)substituted alkylene; Z = (un)substituted OH, NH2, SOmNH2, etc.; R1 = H, halo, CN, etc.] which may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders, were prepared E.g., a multi-step synthesis of II, starting from 2,6-dichloropyrazine and 4-(ethylamino)piperidine-4-

carboxamide, was given. Exemplified compds. I were tested at CB1 receptor. Thus, II as many other representative compds. I showed IC50 of 2  $\mu$ M or less. Pharmaceutical compns. and methods for using compds. I to treat disorders responsive to CB1 modulation are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.

IT 16590-41-3, Naltrexone 34911-55-2,

**Bupropion**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(preparation of substituted heteroaryl compds. useful in treatment of diseases responsive to CB1 activation)

RN 16590-41-3 CAPLUS

CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)

